The United Kingdom, the United States, the European Union and Canada began a rolling review of the COVID-19 vaccine NVX-CoV2373

Recently published Phase III clinical trials have shown that Novavax's COVID-19 vaccine has 89.3% efficacy.
, the United Kingdom, the United States, the European Union and Canada began a rolling review of Novavax's COVID-19 vaccine.
the rolling review process for the vaccine, NVX-CoV2373, has begun with a number of regulatory agencies, including the European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), the Uk Medicines and Healthcare Products Agency (MHRA) and Health Canada.
The regulator's rolling review of our non-clinical and early clinical data will help speed up the review process and bring us closer to providing safe and effective vaccines globally," said Gregory Glenn, president of research and development at Novavax.
phase III trial conducted in the UNITED Kingdom, the first interim analysis found 56 cases of COVID-19 in the placebo group and 6 cases in the NVX-CoV2373 group.
this reflects a point estimate of 89.3 per cent for the vaccine, with preliminary analysis indicating that UK mutants have been detected in more than 50 per cent of PCR-confirmed symptomatic cases.
the efficacy of the vaccine for strains, the researchers found that NVX-CoV2373 had an effective rate of 95.6% for the original COVID-19 strain and 85.6% for the UK mutants.
, the vaccine was found to be 60 per cent effective against mild, moderate and severe COVID-19 in phase IIb trials conducted in South Africa.
study, 29 cases were observed in the placebo group and 15 in the vaccine group.
study, 92.6 per cent of cases were south African mutants.